DK1064382T3 - Homologe polypeptider til VEGF og BMP1 - Google Patents

Homologe polypeptider til VEGF og BMP1

Info

Publication number
DK1064382T3
DK1064382T3 DK99912362T DK99912362T DK1064382T3 DK 1064382 T3 DK1064382 T3 DK 1064382T3 DK 99912362 T DK99912362 T DK 99912362T DK 99912362 T DK99912362 T DK 99912362T DK 1064382 T3 DK1064382 T3 DK 1064382T3
Authority
DK
Denmark
Prior art keywords
vegf
bmp1
homologous polypeptides
growth factor
vascular endothelial
Prior art date
Application number
DK99912362T
Other languages
Danish (da)
English (en)
Inventor
Napoleone Ferrara
Sophia S Kuo
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/040,220 external-priority patent/US6391311B1/en
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DK1064382T3 publication Critical patent/DK1064382T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Materials For Medical Uses (AREA)
DK99912362T 1998-03-17 1999-03-10 Homologe polypeptider til VEGF og BMP1 DK1064382T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/040,220 US6391311B1 (en) 1998-03-17 1998-03-17 Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1
US18421698A 1998-11-02 1998-11-02
PCT/US1999/005190 WO1999047677A2 (en) 1998-03-17 1999-03-10 Polypeptides homologous to vegf and bmp1

Publications (1)

Publication Number Publication Date
DK1064382T3 true DK1064382T3 (da) 2008-12-08

Family

ID=26716852

Family Applications (2)

Application Number Title Priority Date Filing Date
DK08012659.2T DK2016951T3 (da) 1998-03-17 1999-03-10 VEGF- og BMP1-homologe polypeptider
DK99912362T DK1064382T3 (da) 1998-03-17 1999-03-10 Homologe polypeptider til VEGF og BMP1

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK08012659.2T DK2016951T3 (da) 1998-03-17 1999-03-10 VEGF- og BMP1-homologe polypeptider

Country Status (14)

Country Link
US (11) US6455283B1 (de)
EP (2) EP1064382B1 (de)
JP (3) JP4532733B2 (de)
AT (1) ATE405651T1 (de)
AU (1) AU758353B2 (de)
CA (1) CA2322792C (de)
CY (2) CY1108500T1 (de)
DE (1) DE69939374D1 (de)
DK (2) DK2016951T3 (de)
ES (2) ES2389387T3 (de)
HK (1) HK1125853A1 (de)
IL (5) IL138488A0 (de)
PT (1) PT2016951E (de)
WO (1) WO1999047677A2 (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000053758A2 (en) * 1999-03-08 2000-09-14 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US6455283B1 (en) 1998-03-17 2002-09-24 Genentech, Inc. Nucleic acids encoding vascular endothelial cell growth factor-E (VEGF-E)
CA2319112C (en) 1998-02-13 2003-10-28 Genetrace Systems, Inc. Use of ribozymes for functionating genes
WO1999044533A1 (en) * 1998-03-06 1999-09-10 Crosscart, Inc. Soft tissue xenografts
EP0984063A3 (de) * 1998-08-31 2000-08-16 Eli Lilly And Company Vegf-verwandtes gen und protein
US6432673B1 (en) 1998-12-07 2002-08-13 Zymogenetics, Inc. Growth factor homolog ZVEGF3
US6663870B2 (en) * 1998-12-07 2003-12-16 Zymogenetics, Inc. Methods for promoting growth of bone using zvegf3
EP1988102B1 (de) * 1998-12-07 2013-08-21 ZymoGenetics, Inc. Wachstumsfaktor homolog ZVEGF3
US6783953B1 (en) 1998-12-22 2004-08-31 Janssen Pharmaceutica N.V. Vascular endothelial growth factor-X
EP1141293B1 (de) * 1998-12-22 2007-08-01 Janssen Pharmaceutica N.V. Vaskulärer endothelialer wachstumsfaktor x
WO2000039284A1 (en) * 1998-12-30 2000-07-06 Millennium Pharmaceuticals, Inc. Secreted proteins and nucleic acids encoding them
AU3737500A (en) * 1999-03-12 2000-09-28 Genentech Inc. Method of preventing the death of retinal neurons and treating ocular diseases
AU4008500A (en) * 1999-04-06 2000-10-23 Eli Lilly And Company Platelet-derived growth factor related gene and protein
US6630142B2 (en) * 1999-05-03 2003-10-07 Zymogenetics, Inc. Method of treating fibroproliferative disorders
CA2386383A1 (en) * 1999-10-07 2001-04-12 Curagen Corporation Growth factor polypeptides and nucleic acids encoding same
AU8031700A (en) * 1999-10-21 2001-04-30 Zymogenetics Inc. Method of treating fibrosis
US6893637B1 (en) * 1999-10-21 2005-05-17 Zymogenetics, Inc. Method of treating fibrosis
AU1430601A (en) * 1999-11-02 2001-05-14 Eli Lilly And Company Methods of using lp8, a pdgf-related protein, to treat musculoskeletal disorders
EP1252308A2 (de) * 2000-01-19 2002-10-30 Parkash S. Gill Pharmazeutische zubereitungen und behandlungsmethoden, die auf vegf antisense-oligonucleotiden basieren
US7141607B1 (en) 2000-03-10 2006-11-28 Insite Vision Incorporated Methods and compositions for treating and inhibiting retinal neovascularization
CA2403829A1 (en) * 2000-03-28 2001-10-04 Ludwig Institute For Cancer Research Non-human transgenic animals expressing platelet-derived growth factor c (pdgf-c) and uses thereof
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
US20040023863A1 (en) * 2000-04-06 2004-02-05 Franco Wayne P. Methods of use growth factors for treating heart disease
US20070111935A1 (en) * 2000-04-06 2007-05-17 Franco Wayne P Combination growth factor therapy and cell therapy for treatment of acute and chronic diseases of the organs
US7166280B2 (en) * 2000-04-06 2007-01-23 Franco Wayne P Combination growth factor therapy and cell therapy for treatment of acute and chronic heart disease
US20050277576A1 (en) * 2000-04-06 2005-12-15 Franco Wayne P Combination growth factor therapy and cell therapy for treatment of acute and chronic diseases of the organs
AU6896801A (en) * 2000-04-12 2001-10-23 Vlaams Interuniv Inst Biotech Use of vegf and homologues to treat neuron disorders
WO2001085796A2 (en) * 2000-05-12 2001-11-15 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Use of inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumour formation and/or vascular leakage
EP1311277A4 (de) * 2000-07-18 2004-08-25 Joslin Diabetes Center Inc Methoden zur fibrose-modulation
US20020091082A1 (en) * 2000-09-13 2002-07-11 Aiello Lloyd P. Methods of modulating symptoms of hypertension
US20040086507A1 (en) * 2000-10-19 2004-05-06 Kenya Shitara Antibody inhibiting vplf activity
US7067317B2 (en) 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
AU2002228841C1 (en) 2000-12-07 2006-11-23 Sangamo Biosciences, Inc Regulation of angiogenesis with zinc finger proteins
US20020141970A1 (en) * 2001-03-05 2002-10-03 Pettit Dean K. Stable aqueous solutions of granulocyte macrophage colony-stimulating factor
CA2439612A1 (en) 2001-03-09 2002-09-19 Janssen Pharmaceutica N.V. Modulation of smooth muscle cell proliferation
US6913762B2 (en) * 2001-04-25 2005-07-05 Mayo Foundation For Medical Education And Research Stent having non-woven framework containing cells
US7981863B2 (en) 2001-09-19 2011-07-19 Neuronova Ab Treatment of Parkinson's disease with PDGF
EP1463531B1 (de) * 2001-12-11 2011-09-28 Fibrogen, Inc. Verfahren zur hemmung okularer vorgänge
WO2003092665A2 (en) * 2002-05-02 2003-11-13 Massachusetts Eye And Ear Infirmary Ocular drug delivery systems and use thereof
WO2003094617A2 (en) * 2002-05-06 2003-11-20 Genentech, Inc. Use of vegf for treating bone defects
US20060122387A1 (en) * 2002-06-13 2006-06-08 Cti Europe S.R.L. Derivatives of chromen-2-one as inhibitors of vegf production in mammalian cells
US20040052161A1 (en) * 2002-09-17 2004-03-18 Steven Liao Mechanical clock having wireless manipulation and adjustment function
AU2003288027A1 (en) 2002-11-16 2004-06-15 Dade Behring Marburg Gmbh Scd40l, papp-a and placental growth factor (plgf) used as a biochemical marker combination in cardiovascular diseases
WO2005069906A2 (en) * 2004-01-16 2005-08-04 Yale University Methods and compositions relating to vascular endothelial growth factor and th2 mediated inflammatory diseases
US20050282233A1 (en) * 2004-03-05 2005-12-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for VEGF/PDGF family of growth factors
WO2005087177A2 (en) * 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Chimeric anti-vegf-d antibodies and humanized anti-vegf-d antibodies and methods of using same
US8415315B2 (en) 2004-05-06 2013-04-09 University Of Central Florida Research Foundation, Inc. Methods and compositions for inhibiting the proliferation of cancer cells
PL1755647T3 (pl) 2004-05-27 2011-01-31 Vib Vzw Leczenie stwardnienia zanikowego bocznego
US20060045902A1 (en) * 2004-09-01 2006-03-02 Serbousek Jon C Polymeric wrap for in vivo delivery of osteoinductive formulations
DE102004051847B4 (de) * 2004-10-25 2008-09-18 Dade Behring Marburg Gmbh Verhältnis von PIGF und Flt-1 als prognostischer Parameter bei kardio-vaskulären Erkrankungen
EA013970B1 (ru) 2005-03-24 2010-08-30 Тромбоджиникс Н.В. Антитела к плацентарному фактору роста и способы их применения
ATE502956T1 (de) 2005-08-15 2011-04-15 Vegenics Pty Ltd Modifizierte vegf und pdgf mit verbesserten angiogenen eigenschaften
AU2007254243B2 (en) 2006-05-17 2013-06-13 Ludwig Institute For Cancer Research Targeting VEGF-B regulation of fatty acid transporters to modulate human diseases
ES2354922B1 (es) 2009-09-02 2012-02-07 Fundacion Institut De Recerca De L'hospital Universitari Vall D'hebron Marcadores para la selección de terapias personalizadas para el tratamiento del c�?ncer.
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
EA018848B1 (ru) * 2010-10-20 2013-11-29 Вадим Юльевич ШАНИН Иммунологически активное вещество, способ его получения, биозонд на его основе и способ диагностики состояния здоровья с применением биозонда, фармацевтическая композиция и способ лечения с использованием фармацевтической композиции
PL2785739T3 (pl) 2011-12-01 2017-10-31 Thrombogenics Nv Poprawa wyniku trabekulektomii
BR112014025560A2 (pt) 2012-04-24 2017-07-04 Thrombogenics Nv anticorpos anti-pdgf-c
CN104768567B (zh) * 2012-05-18 2017-07-11 奥塔哥创业有限公司 用于伤口愈合的联合治疗和组合物
US20160024181A1 (en) 2013-03-13 2016-01-28 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
CN105713095B (zh) * 2016-03-14 2021-05-07 南京安吉生物科技有限公司 一种多功能融合多肽及其制备方法和应用
KR101943081B1 (ko) 2017-08-31 2019-01-29 (주)케어젠 주름 개선 활성을 나타내는 펩타이드 및 이의 용도

Family Cites Families (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2035733A (en) * 1935-06-10 1936-03-31 Marathon Electric Mfg Fan motor mounting
US2813673A (en) * 1953-07-09 1957-11-19 Gilbert Co A C Tiltable oscillating fan
US2765977A (en) * 1954-10-13 1956-10-09 Morrison Hackley Electric ventilating fans
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
DE3169595D1 (en) 1980-11-10 1985-05-02 Gersonde Klaus Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4568243A (en) * 1981-10-08 1986-02-04 Barry Wright Corporation Vibration isolating seal for mounting fans and blowers
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
JPS58118008A (ja) 1982-01-06 1983-07-13 Nec Corp デ−タ処理装置
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
ATE59966T1 (de) 1983-09-26 1991-02-15 Ehrenfeld Udo Mittel und erzeugnis fuer die diagnose und therapie von tumoren sowie zur behandlung von schwaechen der zelligen und humoralen immunabwehr.
EP0143949B1 (de) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmazeutische Zusammensetzung mit Gehalt an Urokinase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4736866A (en) 1984-06-22 1988-04-12 President And Fellows Of Harvard College Transgenic non-human mammals
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4703152A (en) * 1985-12-11 1987-10-27 Holmes Products Corp. Tiltable and adjustably oscillatable portable electric heater/fan
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5631142A (en) 1986-07-01 1997-05-20 Genetics Institute, Inc. Compositions comprising bone morphogenetic protein-2 (BMP-2)
US5013649A (en) 1986-07-01 1991-05-07 Genetics Institute, Inc. DNA sequences encoding osteoinductive products
US5106748A (en) 1986-07-01 1992-04-21 Genetics Institute, Inc. Dna sequences encoding 5 proteins
IL83003A (en) * 1986-07-01 1995-07-31 Genetics Inst Factors that soak bone formation
US5543394A (en) 1986-07-01 1996-08-06 Genetics Institute, Inc. Bone morphogenetic protein 5(BMP-5) compositions
US4877864A (en) 1987-03-26 1989-10-31 Genetics Institute, Inc. Osteoinductive factors
US4850804A (en) * 1986-07-07 1989-07-25 Tatung Company Of America, Inc. Portable electric fan having a universally adjustable mounting
EP0257956B2 (de) 1986-08-19 2000-11-22 Genentech, Inc. Verwendung von Polypeptidwuchsstoffen und Zytokinen zur Herstellung eines Geräts und einer Dispersion
EP0266032A1 (de) 1986-08-29 1988-05-04 Beecham Group Plc Modifiziertes fibrinolytisches Enzym
US5010182A (en) 1987-07-28 1991-04-23 Chiron Corporation DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
EP0308936B1 (de) 1987-09-23 1994-07-06 Bristol-Myers Squibb Company Antikörper-Heterokonjugate zur Töting von HIV-infizierten Zellen
GB8724885D0 (en) 1987-10-23 1987-11-25 Binns M M Fowlpox virus promotors
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
AU4005289A (en) 1988-08-25 1990-03-01 Smithkline Beecham Corporation Recombinant saccharomyces
US5240848A (en) 1988-11-21 1993-08-31 Monsanto Company Dna sequences encoding human vascular permeability factor having 189 amino acids
US5147638A (en) 1988-12-30 1992-09-15 Oklahoma Medical Research Foundation Inhibition of tumor growth by blockade of the protein C system
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
US5332671A (en) 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
CA2062795A1 (en) 1989-06-29 1990-12-30 Michael W. Fanger Bispecific reagents for aids therapy
CA2020729A1 (en) 1989-07-19 1991-01-20 Michael C. Kiefer Bone morphogenetic protein
DE69027961T2 (de) 1989-09-06 1997-01-09 Takeda Chemical Industries Ltd Protein, DNA und ihre Verwendung
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5126323A (en) 1989-11-16 1992-06-30 Genetics Institute, Inc. Homogeneous purified k-fgf and compositions containing the same
USD325435S (en) * 1990-09-24 1992-04-14 Vornado Air Circulation Systems, Inc. Fan support base
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
JPH06507398A (ja) 1991-05-14 1994-08-25 リプリジェン　コーポレーション Ｈｉｖ感染治療のための異種複合抗体
US5382569A (en) 1991-05-16 1995-01-17 Warner-Lambert Company Endotherlin antagonists
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
CA2108770C (en) 1991-06-25 2007-04-03 John M. Wozney Bmp-9 compositions
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5296769A (en) * 1992-01-24 1994-03-22 Electrolux Corporation Air guide assembly for an electric motor and methods of making
CA2134773A1 (en) 1992-06-04 1993-12-09 Robert J. Debs Methods and compositions for in vivo gene therapy
GB9214857D0 (en) 1992-07-13 1992-08-26 Medical Res Council Human nucleic acid fragments and their use
DK0666868T4 (da) * 1992-10-28 2006-09-18 Genentech Inc Anvendelse af anti-VEGF-antistoffer til behandling af cancer
PL174721B1 (pl) 1992-11-13 1998-09-30 Idec Pharma Corp Przeciwciało monoklonalne anty-CD20
US5310313A (en) * 1992-11-23 1994-05-10 Chen C H Swinging type of electric fan
EP0616812B1 (de) 1993-03-24 1999-11-03 Berlex Biosciences Kombination von Antihormonale und bindende Moleküle zur Krebsbehandlung
ATE522621T1 (de) 1993-04-05 2011-09-15 Univ Utah Res Found Diagnose und behandlung von williams syndrom
US5637480A (en) 1993-05-12 1997-06-10 Genetics Institute, Inc. DNA molecules encoding bone morphogenetic protein-10
US5641756A (en) * 1993-07-27 1997-06-24 Hybridon, Inc. Modified VEGF oligonucleotides
ATE326234T1 (de) 1993-08-26 2006-06-15 Genetics Inst Llc Menschliche knochen-morphogenetische proteine zur verwendung bei neuronaler regeneration
US5773223A (en) 1993-09-02 1998-06-30 Chiron Corporation Endothelin B1, (ETB1) receptor polypeptide and its encoding nucleic acid methods, and uses thereof
DE69434651T2 (de) 1993-12-07 2007-03-08 Genetics Institute, Inc., Cambridge Bmp-12, bmp-13 und diese enthaltende sehne-induzierende zusammensetzungen
US5399677A (en) 1993-12-07 1995-03-21 Genetics Institute, Inc. Mutants of bone morphogenetic proteins
JP3906314B2 (ja) 1994-04-25 2007-04-18 ジェネンテク・インコーポレイテッド カルジオトロフィンおよびその使用
WO2000053758A2 (en) 1999-03-08 2000-09-14 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US5454419A (en) 1994-09-19 1995-10-03 Polybore, Inc. Method for lining a casing
US5681746A (en) 1994-12-30 1997-10-28 Chiron Viagene, Inc. Retroviral delivery of full length factor VIII
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US5518370A (en) * 1995-04-03 1996-05-21 Duracraft Corporation Portable electric fan with swivel mount
SG68529A1 (en) 1995-05-25 1999-11-16 Univ Singapore The use of des-aspartate-angiotensin i (agr-val-tyr-ile-his-pro-phe-his-leu) as an anti-cardiac hypertrophic agent
BR9707785A (pt) * 1996-02-28 1999-07-27 Bayer Ag Parapoxvírus que contém dna estrangeiro preparação dos mesmos e uso dos mesmos em vacinas
AU2582897A (en) 1996-03-15 1997-10-01 Millennium Pharmaceuticals, Inc. Compositions and methods for the diagnosis, prevention, and treatment of neoplastic cell growth and proliferation
CA2258721C (en) * 1996-07-12 2014-09-09 Genentech, Inc. Chimeric heteromultimer adhesins
AU3783497A (en) 1996-08-09 1998-03-06 Yamanouchi Pharmaceutical Co., Ltd. Metabotropic glutamate receptor agonists
DK1749836T3 (da) * 1996-08-23 2009-08-31 Vegenics Ltd Rekombinant vaskulær endothelcellevækstfaktor D
PT973804E (pt) 1997-04-07 2007-03-30 Genentech Inc Anticorpos anti-vegf
USD398983S (en) * 1997-08-08 1998-09-29 Vornado Air Circulation Systems, Inc. Fan
US6455283B1 (en) * 1998-03-17 2002-09-24 Genentech, Inc. Nucleic acids encoding vascular endothelial cell growth factor-E (VEGF-E)
US6391311B1 (en) * 1998-03-17 2002-05-21 Genentech, Inc. Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1
WO1999037671A1 (en) 1998-01-27 1999-07-29 Eli Lilly And Company Vegf related gene and protein
NZ507435A (en) 1998-03-10 2003-12-19 Genentech Inc Novel polypeptides and nucleic acids with homology to cornichon
CA2334075A1 (en) 1998-07-15 2000-01-27 Human Genome Sciences, Inc. Bone morphogenic protein
CA2344561A1 (en) 1998-09-30 2000-04-06 Ludwig Institute For Cancer Research Platelet-derived growth factor c, dna coding therefor, and uses thereof
EP1127122A2 (de) 1998-10-28 2001-08-29 Incyte Pharmaceuticals, Inc. Wachstumsfaktor verwandte moleküle
US20030027998A1 (en) * 1998-10-30 2003-02-06 Holtzman Douglas A. Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
JP3695642B2 (ja) 1998-12-01 2005-09-14 ジェネンテック・インコーポレーテッド 血管形成及び心臓血管新生の促進又は阻害
EP1988102B1 (de) 1998-12-07 2013-08-21 ZymoGenetics, Inc. Wachstumsfaktor homolog ZVEGF3
US6432673B1 (en) * 1998-12-07 2002-08-13 Zymogenetics, Inc. Growth factor homolog ZVEGF3
EP1141293B1 (de) 1998-12-22 2007-08-01 Janssen Pharmaceutica N.V. Vaskulärer endothelialer wachstumsfaktor x
WO2000039284A1 (en) 1998-12-30 2000-07-06 Millennium Pharmaceuticals, Inc. Secreted proteins and nucleic acids encoding them
US6155782A (en) * 1999-02-01 2000-12-05 Hsu; Chin-Tien Portable fan
AU4008500A (en) 1999-04-06 2000-10-23 Eli Lilly And Company Platelet-derived growth factor related gene and protein
EP1177293A1 (de) 1999-05-03 2002-02-06 ZymoGenetics, Inc. Wachstumsfaktorhomolog zvegf4
EP1157242A1 (de) * 1999-12-06 2001-11-28 The Holmes Group, Inc. Schwenkbarer wärmetauscher
US20030181377A1 (en) * 2002-02-12 2003-09-25 Vanderbilt University Inhibition of VEGF receptor signaling reverses tumor resistance to radiotherapy
BR0201397B1 (pt) * 2002-04-19 2011-10-18 arranjo de montagem para um ventilador de refrigerador.
US6830433B2 (en) * 2002-08-05 2004-12-14 Kaz, Inc. Tower fan
US7059826B2 (en) * 2003-07-25 2006-06-13 Lasko Holdings, Inc. Multi-directional air circulating fan
US20050128698A1 (en) * 2003-12-10 2005-06-16 Huang Cheng Y. Cooling fan
US20050282233A1 (en) * 2004-03-05 2005-12-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for VEGF/PDGF family of growth factors
US7088913B1 (en) * 2004-06-28 2006-08-08 Jcs/Thg, Llc Baseboard/upright heater assembly
CN2835669Y (zh) * 2005-09-16 2006-11-08 霍树添 立柱式电风扇的送风机构

Also Published As

Publication number Publication date
US20040219640A1 (en) 2004-11-04
IL189571A0 (en) 2009-02-11
EP1064382B1 (de) 2008-08-20
AU3075099A (en) 1999-10-11
JP2013224300A (ja) 2013-10-31
HK1125853A1 (en) 2009-08-21
AU758353C (en) 1999-10-11
ES2313778T3 (es) 2009-03-01
US6620784B1 (en) 2003-09-16
IL138488A0 (en) 2001-10-31
WO1999047677A3 (en) 1999-11-11
ATE405651T1 (de) 2008-09-15
AU758353B2 (en) 2003-03-20
US20100331251A1 (en) 2010-12-30
US7575879B2 (en) 2009-08-18
DK2016951T3 (da) 2012-09-24
US20080095773A1 (en) 2008-04-24
IL189573A0 (en) 2009-02-11
IL189572A0 (en) 2009-02-11
WO1999047677A2 (en) 1999-09-23
US20070031929A1 (en) 2007-02-08
US20110319327A1 (en) 2011-12-29
JP2004515201A (ja) 2004-05-27
EP2016951B1 (de) 2012-06-27
DE69939374D1 (de) 2008-10-02
US20080299119A1 (en) 2008-12-04
US20090012003A1 (en) 2009-01-08
EP2016951A1 (de) 2009-01-21
US6455283B1 (en) 2002-09-24
US20090264370A9 (en) 2009-10-22
IL138488A (en) 2008-06-05
IL189572A (en) 2013-01-31
US7371377B2 (en) 2008-05-13
JP4532733B2 (ja) 2010-08-25
JP5473441B2 (ja) 2014-04-16
US7494977B2 (en) 2009-02-24
JP2010001292A (ja) 2010-01-07
CY1113126T1 (el) 2016-04-13
CA2322792A1 (en) 1999-09-23
US20040235740A1 (en) 2004-11-25
JP5931801B2 (ja) 2016-06-08
PT2016951E (pt) 2012-09-27
CA2322792C (en) 2010-09-14
EP1064382A2 (de) 2001-01-03
CY1108500T1 (el) 2014-04-09
ES2389387T3 (es) 2012-10-25
US20030113870A1 (en) 2003-06-19

Similar Documents

Publication Publication Date Title
DK1064382T3 (da) Homologe polypeptider til VEGF og BMP1
DE69028535T2 (de) Herstellung des vaskulären endothelialen zellwachstumsfaktors
DE3869577D1 (de) Injizierbare zusammensetzung zur wiederherstellung von knochen.
NL300116I1 (nl) Nieuwe osteoinductieve samenstellingen.
KR930703004A (ko) 맥관형성 펩티드
DK0643767T3 (da) Osteogene peptider
ATE404668T1 (de) Wachstumsfaktor-homologe zvegf-3
CA2104678A1 (en) Protein-induced morphogenesis
HU9200548D0 (en) Improved activity process of recombined proteins
DE59810198D1 (de) Myc-bindende Zinkfinger-Proteine, ihre Herstellung und ihre Verwendung
WO2001005810A3 (de) CYCLISCHE PEPTIDDERIVATE ALS INHIBITOREN DES INTEGRINS αvβ¿6?
ATE291088T1 (de) Immunologisch aktive proteine von borrelia burgdorferi, dafür kodierende nukleinsäuren sowie deren verwendung in testkits und als impfstoffe
ATE123056T1 (de) Ancrod-proteine, ihre herstellung und verwendung.
DE59108261D1 (de) Peptide des HIV-gag Proteins, ihre Herstellung und Verwendung
ES2186501A1 (es) Factor de crecimiento fibroblastico basico con un dominio de union especifico a colegeno.
ATE130872T1 (de) Ancrod ähnliche proteine, ihre herstellung und verwendung.
ATE432985T1 (de) Polypeptide mit aktivität der stimulierung von neutrophilen
WO1999062931A3 (en) A cell density signal protein suitable for treatment of connective tissue injuries and defects